Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Open Label Multicenter Clinical Trial to Evaluate the Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease

Next Previous
Trial Profile

A Phase 2a, Open Label Multicenter Clinical Trial to Evaluate the Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sonpiretigene isteparvovec (Primary)
  • Indications Stargardt disease
  • Focus Adverse reactions
  • Acronyms STARLIGHT
  • Sponsors Nanoscope Therapeutics

Most Recent Events

  • 12 Sep 2024 According to Nanoscope Therapeutics media release, company announced a productive End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of severe vision loss due to Stargardt Macular Degeneration (SMD), supporting advancement of MCO-010 to a Phase 3 registrational trial.
  • 30 Oct 2023 According to a Nanoscope Therapeutics media release, topline data from the this trial will present at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting and Eyecelerator AAO 2023 taking place in San Francisco, California.
  • 26 Oct 2023 Status changed from active, no longer recruiting to completed, According to a Nanoscope Therapeutics media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top